According to research reviewed by Gram, GLP-1 medications helped women with PCOS and excess weight lose about 2.8 kilograms more than control treatments in a 2026 analysis. Their waist size also dropped by about 3.5 centimeters more. The evidence is rated low certainty because the trials were small and short, so these results are promising but not yet definitive.

Women with polycystic ovary syndrome (PCOS) who also carry extra weight often struggle to lose it through diet, exercise, or metformin alone. According to research reviewed by Gram, a 2026 analysis of five randomized trials with 319 women found that GLP-1 medications, a class of drugs that lowers appetite and slows digestion, helped these women lose more weight than control treatments. On average, participants lost about 2.8 kilograms (roughly 6 pounds) more, and their waist size shrank by about 3.5 centimeters. The researchers caution that the trials were small, followed people for a short time, and had uneven quality. Because of this, the results are promising but not yet conclusive, and more large, long-term studies are needed before these findings can guide routine care.

Key Statistics

A 2026 meta-analysis of five randomized controlled trials with 319 women found that GLP-1 receptor agonists reduced body weight by an average of 2.80 kilograms more than control treatments in women with polycystic ovary syndrome and overweight or obesity.

The same 2026 meta-analysis reported that waist circumference decreased by an average of 3.53 centimeters more with GLP-1 receptor agonists, although the researchers rated the certainty of this evidence as low.

The Quick Take

  • What they studied: Researchers wanted to know whether GLP-1 medications, such as semaglutide and liraglutide, help women with PCOS and excess weight lose more weight and reduce belly fat than other treatments.
  • Who participated: The review pooled five clinical trials that included 319 women of reproductive age who had PCOS and were overweight or living with obesity. The trials compared GLP-1 medications with placebo pills, metformin, or calorie-controlled diets.
  • Key finding: Women taking GLP-1 medications lost an average of 2.8 kilograms more than those in the comparison groups. Their waist measurements also dropped by about 3.5 centimeters more. The evidence behind these numbers is rated as low certainty.
  • What it means for you: If you have PCOS and extra weight, these results suggest GLP-1 medications may be a helpful option to discuss with your doctor. They are not a stand-alone cure, and the benefits seen in these trials were modest. Any decision should weigh side effects, cost, and your personal health history.

The Research Details

This study is a systematic review and meta-analysis. In plain terms, the researchers searched many medical databases and trial registries for studies published between 2015 and 2025. They looked for randomized controlled trials, which are studies where people are assigned to treatments by chance. This method helps reduce bias because neither the participants nor the researchers decide who gets which treatment.

Once the team found five trials that met their rules, they combined the results using a statistical method called meta-analysis. Think of it as pooling the numbers from several small studies to see a clearer overall picture. Because the trials measured weight in slightly different ways, the researchers used statistical adjustments so the results could be compared fairly.

The team also checked each trial for potential bias, such as weak randomization or missing data, and rated how confident they could be in the overall evidence. They also ran sensitivity checks, which means they repeated the analysis in different ways to see whether the answer changed. The direction of the results stayed consistent.

A meta-analysis can be more useful than a single trial because it combines data from several studies and can reveal patterns that a small trial might miss. Randomized trials are the strongest design for testing whether a treatment causes a change, so limiting the review to them makes the findings more trustworthy than observational studies would be.

Still, pooling only five small trials means each study has an outsized influence on the final numbers. That is why the approach is useful for spotting a trend, but it cannot provide the final word on how well these drugs work for women with PCOS.

The review followed an established protocol and used recognized tools to judge bias (RoB 2) and the strength of evidence (GRADE), which are good signs of careful work. However, the researchers themselves rated the evidence as low certainty for weight, body shape, and belly fat outcomes. This means future studies could easily change the answer.

Readers should also know that the total group was small at 319 women, the trials lasted only a short time, and some trials had methodological concerns. These factors limit how confidently the results can be applied to all women with PCOS.

What the Results Show

The main outcome was body weight. Across the five trials, women taking GLP-1 medications lost an average of 2.80 kilograms more than women in the comparison groups. The statistical range of this estimate runs from about 1.66 to 3.94 kilograms, which means the true effect is likely to fall somewhere in that span. Since the entire range sits below zero, the weight difference is unlikely to be due to chance alone.

Body mass index (BMI), a measure that compares weight to height, dropped by about 1.02 points more in the medication groups. This is a modest change. For a woman of average height, it would likely translate into a few kilograms of body weight, which fits with the weight results above.

Waist circumference, a common marker of belly fat, decreased by about 3.53 centimeters more with GLP-1 medications. Belly fat matters because it is linked to insulin resistance and heart risk, so this change is meaningful even though the absolute numbers are small.

The researchers also looked at visceral fat, the fat stored deep inside the abdomen around organs. Only three trials measured it, and the pooled result suggested a reduction. However, the estimate was imprecise, so this finding should be treated as a rough signal rather than a firm conclusion.

The team ran an exploratory comparison between trials that used GLP-1 medications alone and trials that combined them with other treatments. The medication-only trials showed a larger average weight loss, about 3.43 kilograms compared with 2.04 kilograms. The difference was statistically notable, but the number of trials was small and the comparison groups varied. The authors describe this as a hypothesis to test in future research, not as proof that one approach works better.

The review also found that the medications produced consistent results across sensitivity analyses, which adds some confidence that the main finding is not a fluke of one particular trial. Specific side effect data were not the focus of this summary, so readers should review the safety profile of each medication with a healthcare provider.

Lifestyle changes and metformin are the usual first steps for PCOS-related weight problems, but their weight-loss effects are generally modest. This review suggests that GLP-1 medications, which are already used for diabetes and obesity in the general population, may offer a larger weight-loss effect in women with PCOS. That fits with broader obesity research showing these drugs produce meaningful weight loss in many groups.

At the same time, the size of the benefit found here is smaller than what has been reported in large obesity trials of these medications. This may reflect the small number of PCOS-specific studies, differences in the women studied, or the short length of the trials.

The biggest limitation is the small evidence base. Only five trials with 319 women were included, and the trials were clinically varied in their doses, comparison treatments, and lengths. Follow-up was short, so it is unknown whether the weight loss lasts or whether side effects appear over longer periods.

Some of the included trials raised concerns about bias, such as how participants were assigned or how missing data were handled. The researchers rated the overall certainty of the evidence as low, which means the true effects could differ from the estimates reported here.

Finally, the analysis of visceral fat rested on only three trials, and the authors noted that the precision was insufficient. Results that look strong on paper can shift quickly when new data are added, so these numbers should be viewed as preliminary.

The Bottom Line

Research suggests that GLP-1 medications may help women with PCOS and overweight or obesity lose a modest amount of weight and reduce waist size compared with conventional approaches. Confidence in this recommendation is low to moderate, because the evidence comes from a small number of short trials. Women should not begin these medications based on this review alone. Instead, they should discuss the options, including lifestyle changes as the foundation of care, with a qualified healthcare provider who can review their full medical history.

Women of reproductive age with PCOS who have overweight or obesity and have not reached their goals with diet, exercise, or metformin may want to ask their doctor about this option. Clinicians, researchers, and health app users tracking weight and PCOS symptoms may also find these results useful. People who are pregnant, planning a pregnancy, breastfeeding, or who have a history of certain thyroid cancers or pancreatitis should talk with a doctor before considering these drugs. Women without PCOS or without excess weight are not the focus of this research.

In the trials reviewed, weight changes were measured over relatively short periods, so the results describe early and mid-term effects. Many people using GLP-1 medications notice changes within the first few months, but the average benefit seen here was modest. Any realistic expectation should be built around gradual progress over several months, with the understanding that long-term results are still unknown.

Frequently Asked Questions

Can GLP-1 medications help women with PCOS lose weight?

Research shows GLP-1 medications may help. A 2026 analysis of five trials with 319 women found an average extra weight loss of 2.8 kilograms compared with control treatments. Researchers rated the evidence as low certainty, so more long-term studies are needed.

How much weight can women with PCOS expect to lose on GLP-1 drugs?

In a 2026 meta-analysis, women with PCOS taking GLP-1 medications lost about 2.8 kilograms more than comparison groups on average. Their BMI dropped by about 1.02 points. Individual results vary, and the trials followed participants for only a short time.

Do GLP-1 medications reduce belly fat in women with PCOS?

Waist circumference decreased by about 3.53 centimeters more with GLP-1 medications in a 2026 analysis of five trials. A pooled analysis of three trials also suggested reduced visceral fat, but the estimate was imprecise and the evidence was rated low certainty.

Are GLP-1 medications better than metformin for PCOS weight loss?

This review did not directly prove that GLP-1 medications beat metformin. Trials comparing them mostly used placebo, metformin, or calorie-restricted diets as controls. A subgroup comparison suggested larger weight loss with medication alone, but researchers described this as a hypothesis for future testing.

Want to Apply This Research?

  • Log your body weight once a week at the same time of day, such as Monday morning after using the bathroom. Also record your waist circumference once a month using a flexible tape measure placed at the belly button level. Tracking both numbers gives a fuller picture than weight alone.
  • Use the app to set a realistic goal of losing about 0.5 to 1 kilogram per month, which is a gentle pace that matches what many people achieve with steady changes. Pair this with logging at least 150 minutes of moderate activity per week and a daily protein target that helps preserve muscle. Share these logs with your healthcare provider at each visit.
  • Create a rolling 6-month and 12-month review in the app that compares your weight, waist size, menstrual cycle regularity, and energy levels. Add a note field for any medication changes or side effects so patterns can be discussed with your doctor. Review trends rather than daily fluctuations, and update your plan with your healthcare team if progress stalls for three months or more.

This article summarizes a single meta-analysis of five small clinical trials and is for general educational purposes only. It is not medical advice and does not replace consultation with a qualified healthcare provider. GLP-1 medications carry risks and are not appropriate for everyone, including people who are pregnant or planning pregnancy. Do not start, stop, or change any medication based on this article alone.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Weight-loss effects of GLP-1 receptor agonists in reproductive-age women with overweight or obesity and polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. , Minerva endocrinology (2026). PubMed 43046905 | DOI
Topics
GLP-1 medications polycystic ovary syndrome PCOS weight loss waist circumference visceral fat meta-analysis women's health obesity treatment